PH12021550324A1 - 5 to 7 membered heterocyclic amides as jak inhibitors - Google Patents

5 to 7 membered heterocyclic amides as jak inhibitors

Info

Publication number
PH12021550324A1
PH12021550324A1 PH12021550324A PH12021550324A PH12021550324A1 PH 12021550324 A1 PH12021550324 A1 PH 12021550324A1 PH 12021550324 A PH12021550324 A PH 12021550324A PH 12021550324 A PH12021550324 A PH 12021550324A PH 12021550324 A1 PH12021550324 A1 PH 12021550324A1
Authority
PH
Philippines
Prior art keywords
membered heterocyclic
jak inhibitors
heterocyclic amides
compounds
amides
Prior art date
Application number
PH12021550324A
Other languages
English (en)
Inventor
Daniel D Long
Cameron Smith
Corbin Thompson
Original Assignee
Theravance Biopharma R And D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R And D Ip Llc filed Critical Theravance Biopharma R And D Ip Llc
Publication of PH12021550324A1 publication Critical patent/PH12021550324A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH12021550324A 2018-09-04 2021-02-15 5 to 7 membered heterocyclic amides as jak inhibitors PH12021550324A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726583P 2018-09-04 2018-09-04
PCT/US2019/049342 WO2020051139A1 (en) 2018-09-04 2019-09-03 5 to 7 membered heterocyclic amides as jak inhibitors

Publications (1)

Publication Number Publication Date
PH12021550324A1 true PH12021550324A1 (en) 2021-10-04

Family

ID=68051893

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550324A PH12021550324A1 (en) 2018-09-04 2021-02-15 5 to 7 membered heterocyclic amides as jak inhibitors

Country Status (20)

Country Link
US (2) US10836763B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837010B1 (cg-RX-API-DMAC7.html)
JP (1) JP7383696B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210056380A (cg-RX-API-DMAC7.html)
CN (1) CN112703037B (cg-RX-API-DMAC7.html)
AR (1) AR116114A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019335200A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004063A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000515A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021002976A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190686A1 (cg-RX-API-DMAC7.html)
ES (1) ES2955717T3 (cg-RX-API-DMAC7.html)
IL (1) IL281150B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002484A (cg-RX-API-DMAC7.html)
PH (1) PH12021550324A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101751XA (cg-RX-API-DMAC7.html)
TW (1) TWI793365B (cg-RX-API-DMAC7.html)
UA (1) UA127328C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020051139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100990B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3161899A4 (en) 2014-06-30 2017-12-27 Black & Decker Inc. Battery pack for a cordless power tools
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
BR112021004063A2 (pt) * 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
WO2022081872A1 (en) * 2020-10-16 2022-04-21 Gb008, Inc. Janus kinase inhibitors
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN118401508A (zh) * 2021-12-17 2024-07-26 株式会社大熊制药 (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形
AU2025221563A1 (en) * 2024-02-14 2026-07-09 Almirall, S.A. Stat6 inhibitors and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
CA2756989A1 (en) 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ip有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
EP3831830A1 (en) * 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3712152T3 (da) * 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
US10906888B2 (en) * 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
TWI754019B (zh) * 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
BR112021004087A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc processo para preparar inibidores de jak e seus intermediários
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
BR112021004063A2 (pt) * 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR102873783B1 (ko) 2019-02-25 2025-10-21 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 Jak 억제제 화합물 및 그 사용
UA130579C2 (uk) 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途

Also Published As

Publication number Publication date
US20200071325A1 (en) 2020-03-05
KR20210056380A (ko) 2021-05-18
ES2955717T3 (es) 2023-12-05
JP2021535174A (ja) 2021-12-16
CN112703037A (zh) 2021-04-23
IL281150B2 (en) 2024-03-01
AR116114A1 (es) 2021-03-31
IL281150B1 (en) 2023-11-01
US10836763B2 (en) 2020-11-17
SG11202101751XA (en) 2021-03-30
TW202024075A (zh) 2020-07-01
ZA202100990B (en) 2024-09-25
CO2021002976A2 (es) 2021-05-31
EP3837010B1 (en) 2023-07-05
US20210024517A1 (en) 2021-01-28
US11713315B2 (en) 2023-08-01
CL2021000515A1 (es) 2021-07-23
MX2021002484A (es) 2021-05-12
AU2019335200A1 (en) 2021-03-11
JP7383696B2 (ja) 2023-11-20
EP3837010C0 (en) 2023-07-05
BR112021004063A2 (pt) 2021-05-25
CN112703037B (zh) 2023-10-20
EA202190686A1 (ru) 2021-07-23
WO2020051139A1 (en) 2020-03-12
IL281150A (en) 2021-04-29
TWI793365B (zh) 2023-02-21
EP3837010A1 (en) 2021-06-23
UA127328C2 (uk) 2023-07-19

Similar Documents

Publication Publication Date Title
ZA202100990B (en) 5 to 7 membered heterocyclic amides as jak inhibitors
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
PH12021550368A1 (en) Dimethyl amino azetidine amides as jak inhibitors
ZA201802496B (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
GEP20207202B (en) Tyrosine amide derivatives as rho-kinase inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY199220A (en) Heterocyclic compounds as immunomodulators
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
MY199446A (en) Compounds and compositions and uses thereof
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
NZ737536A (en) Substituted benzamides and methods of use thereof
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12021550258A1 (en) Cdk8/19 inhibitors
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена